Logo

Amgen Presents Results of Lumakras (sotorasib) + Vectibix (panitumumab) in P-Ib/II CodeBreaK 101 study for KRAS G12C-Mutated Colorectal Cancer at ESMO21 2021

Share this
Amgen Presents Results of Lumakras (sotorasib) + Vectibix (panitumumab) in P-Ib/II CodeBreaK 101 study for KRAS G12C-Mutated Colorectal Cancer at ESMO21 2021

Tuba Khan

Amgen Presents Results of Lumakras (sotorasib) + Vectibix (panitumumab) in P-Ib/II CodeBreaK 101 study for KRAS G12C-Mutated Colorectal Cancer at ESMO21 2021

Shots:

  • The P-Ib/II CodeBreaK 101 study evaluates Lumakras + Vectibix in 31 patients with KRAS G12C-mutated advanced CRC
  • The results demonstrated ORR (27%) among 26 patients in the efficacy analysis- DCR (81%)- 33% of patients experienced a response in the expansion cohort- no patients experienced dose-limiting toxicities during the 28 days following initial treatment. The therapy also demonstrated the efficacy and safety
  • Amgen has completed an enrolment in P-III CodeBreaK 200 trial to evaluate sotorasib vs docetaxel in patients with KRAS G12C-mutated NSCLC. Lumakras is also being studied in multiple other solid tumors

Click here to­ read full press release/ article | Ref: PR Newswire | Image: Wall Street Journal

Click Here

Share this article on WhatsApp, LinkedIn and Twitter

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family